One hundred fifty seven men with candidal balanitis were entered in a randomised, open-label parallel-group multicentre study comparing efficacy and safety of a single oral 150-mg fluconazole-dose with clotrimazole applied topically twice daily for 7 days. Of 64 fluconazole and 68 clotrimazole treated patients who were evaluable at short term follow up, 92% and 91 % respectively were clinically cured or improved. Candida albicans was eradicated in 78% and 83% of patients respectively. Median time to relief of erythema was 6 days for fluconazole and 7 days for clotrimazole. Twelve of 15 patients who had received previous topical therapy for balanitis said they preferred oral therapy. At the one month follow up visit, 24/36 and 29/33 patients in the two groups were clinically cured or improved. Nine in the fluconazole group experienced a relapse; 6 of these 9 patients reported previous episodes of this infection during the past year. Two patients in the clotrimazole group had a relapse; neither had a history of previous episodes. Mycological eradication was noted in 26/36 and 25/33 patients in the two groups. Both treatment regimens were well tolerated. Thus a single 150 mg dose of fluconazole was comparable in efficacy and safety to clotrimazole cream applied topically for 7 days when administered to patients with balanitis. (Genitourin Med 1996;72:98-102) 
Introduction
Balanitis is an acute or chronic inflammation of the glans penis. The typical case is mild with erythema and symptoms of pain and burning.' 2 However, patients with balanitis can also present with profuse subpreputial discharge, oedema, and various degrees of phimosis. The microorganism most often cultured in symptomatic patients is Candida albicans. [3] [4] [5] [6] [7] There are several factors that predispose patients to the development of balanitis including intercourse with an infected partner, recent antibiotic therapy, and poorly controlled diabetes mellitus.3 4 89 Additionally, balanitis commonly occurs in uncircumcised men.5 9 10 Conventional treatment of candida balanitis consists of topical application of an antifungal cream for a period of 1 to 2 weeks.458 Topical agents are messy and tend to rub off on clothing, which can lead to noncompliance. An alternative to topical therapy is short-course systemic therapy with an oral antifungal drug. Oral treatment tends to result in better patient compliance than topical creams. Better patient compliance to therapeutic regimens usually results in a better overall response to therapy. This is especially important in general practice where compliance tends to be less than in formal clinical studies. In this regard, fluconazole has been considered because of its favourable absorption profile, extensive distribution into tissues, and its lack of serious adverse effects." 12 Single-dose treatment with oral fluconazole is becoming well-accepted as a safe and effective alternative to topical treatment of candida vaginitis. "3 To date, the only published study evaluating single-dose fluconazole in Both treatment regimens were well tolerated. Only one patient in the fluconazole group reported mild diarrhoea 2 days after ingesting the single dose. The diarrhoea resolved spontaneously.
Discussion
Vulvovaginal candidiasis is a common infection in women; more recently, the importance of genital candidiasis in men has become recognized.8915 Over the 10 year period from 1976 to 1986, the number of men with genital candidiasis presenting to a genitourinary clinic in the United Kingdom increased by 75%.14 This infection is frequently associated with a concurrent vaginal candidiasis infection in a sexual partner. The moist epithelium below the prepuce provides ideal growing conditions for microorganisms, especially in uncircumcised men. Bacteria and yeast, especially candida, are abundant in the preputial sac. Although candida is usually saprophytic, this organism may become pathogenic under conditions of lowered local or general resistance. ' 8 Although candidal balanitis is not a serious infection, the distressing symptoms and associated discomfort necessitate rapid and effective treatment. As is evident from our study, as well as previously published balanitis treatment studies,'51-8 the patient's motivation for follow-up evaluation and treatment disappears rapidly. Once the patient realises he has a relatively benign condition and the anxiety of having an abnormal genital condition resolves, compliance with follow-up visit schedules decreases. Therefore, a therapy that provides high cure rates with minimal adverse effects after a single dose is ideal for these patients.
A number of topical and systemic antifungal drugs are available for the treatment of candida balanitis. Topical application with the polyene antifungals, nystatin'6 and natamycin, '7 and the imidazole and triazole antifungals, bifonazole,'8 19 butaconazole,'0 clotrimazole,'5 18 and miconazole,'6 have produced excellent results with short-term mycologic response rates in the range of 77% to 100%. All of the topical therapies, however, require 1 to 2 weeks of application for effective cures, and patient compliance is hampered by the necessary prolonged course of therapy.
The Although the clinical response rate at longterm follow-up was higher for clotrimazole than for fluconazole, there was little difference between treatment groups in the mycologic eradication rate. It is unclear why more clinical relapses occurred 4 weeks after therapy in patients treated with fluconazole, a systemically active agent, as compared with those treated with topical clotrimazole. Several factors, however, should be considered when evaluating the difference in outcomes between the two treatment groups. Our first consideration was that the number of patients with previous episodes of candida balanitis was significantly higher in the fluconazole group. Six of the nine (67%) patients who experienced clinical relapse in the fluconazole group had previous episodes of balanitis. All of these patients had at least two episodes during the previous 12 months. None of the clotrimazole patients in whom clinical relapse occurred reported episodes of balanitis during the previous 12 months. Secondly, of the 10 patients with relapse/reinfection at long-term followup, four fluconazole-treated but only two clotrimazole-treated patients reported having had sexual intercourse during the time between the last two visits. The importance of treating both partners simultaneously is generally recognised.' Thirdly, it is possible that patients in the clotrimazole group practiced better hygiene because they were applying topical medication twice a day. Perhaps future investigations should place greater emphasis on good hygiene, particularly for the benefit of those receiving oral therapy. Another consideration was that perhaps mycologic responders and nonresponders should be compared with respect to fluconazole dose on the basis of mg-per-kg body weight or body mass. Indeed, at the short-term visit heavier patients were more likely to have a response of persistence than eradication. The mean weight of fluconazole-treated patients in whom candida was eradicated was 77.5 kg compared with 83.8 kg for patients who had a response of persistence (p = 002). A final consideration is that global ratings may be inappropriate for detecting small differences in efficacy.
In summary, we found similar clinical and mycologic response rates to treatment with either a single oral 150-mg dose of fluconazole or topical clotrimazole 1% cream administered twice daily for 7 days to patients with candida balanitis. Clinical cure or improvement occurred in over 90% of evaluable patients treated with either fluconazole or clotrimazole, and mycologic eradication rates were comparably high. Both treatments were well-tolerated. Fluconazole given as a single oral dose is a more convenient therapy than conventional multiple-dose topical regimens. These factors may contribute to improved patient acceptability and compliance. Future studies may further define the role of singledose fluconazole in the simultaneous treatment of sexual partners with candidal balanitis and vaginitis, and in the prevention of socalled "ping-pong" infections. 
